Animal Model Market

Animal Model Market

New York, September 2023: According to a new research study by Global Insight Services (GIS), the Animal Model Market is expected to grow rapidly over the next 10 years to reach a value of more than US$ 3.6 billion by 2032.

Non-human organisms, usually animals, are employed in scientific research to examine biological processes, discover disease causes, create new therapies, and gain knowledge about human health and physiology. Animal models are important in many domains, including medicine, pharmacology, genetics, and toxicity. They enable researchers to comprehend complicated biological systems, test ideas, and make forecasts before proceeding to human trials.

Request Sample Pages of this Research Report

Animal Model Market: Market Drivers and Trends

Rise in the usage of the animal models in virology is driving the market expansion. Animal models, including mice, rats, guinea pigs, and nonhuman primates, are critical in investigating the pathophysiology, transmission, and potential therapies for a variety of viral infections and infectious illnesses. These models provide a crucial platform for researchers to better understand the intricate mechanisms of viral replication, host immune responses, and disease development. Animal models have been found to be invaluable tools in virology research, enabling scientists to simulate human illnesses and evaluate the efficiency of antiviral medicines and vaccinations. In the instance of the COVID-19 pandemic, for example, animal models were critical in comprehending the SARS-CoV-2 virus and assessing prospective treatment strategies. Researchers to explore viral entrance, replicating, and dissemination, as well as to evaluate vaccine candidates and antiviral medicines utilized animal models. These studies shed light on the virus’s behaviour and aided in the development of efficient preventative and treatment measures.

Additionally, increase in the CRISPR technology is going to boost the market growth in the coming years. CRISPR allows scientists to modify individual genes in animals with remarkable accuracy, resulting in more precise disease models. Scientists can imitate the genetic abnormalities found in patients by introducing particular mutations linked with human illnesses into animal genomes, allowing for a deeper understanding of disease processes and the evaluation of prospective therapeutic approaches. CRISPR, for example, has been used to investigate cancer, based on a 2022 report by the National Library of Medicine, since the approach offers various new methods to mimic the illness. This involves the creation of pre-clinical cancer models in which CRISPR is used to produce mutations found in human cancer. As a result, rare mutations may be examined in a physiologically appropriate context, and CRISPR technology has sped up the development of these models. CRISPR technology developers Emmanuelle Charpentier and Jennifer Doudna were awarded the Nobel Prize in 2020. These drivers are likely to propel market expansion.

Animal Model Market: Market Restraints and Challenges

To ensure the ethical and appropriate application of animals in scientific research, strict regulatory criteria for animal model utilization are in place. To protect animal welfare, a structure of strong regulations and rigid norms exists. These restrictions are extensive and differ from one country to the next. Typically, regulatory requirements demand that researchers establish the scientific need and possible benefits of utilizing animal models. Institutional animal care and use committees (IACUCs) or equivalent regulatory agencies conduct ethical reviews of research proposals involving animal testing. These committees evaluate the proposed studies’ rationale, design, and welfare issues. Such severe and changeable laws may impede the employing of animal models in scientific research, stifling corporate growth.

Animal Model Market Report Findings

The mice segment is likely to hold the major share of the market in 2022

Based on animal type, the Animal Model Market is segmented into rat, mice, guinea pigs, rabbits, and others. The mice segment is expected to dominate the market during the forecast period. Increased investment and technical improvement in mouse model technologies are expected to fuel market expansion. Furthermore, the growing implications of mouse clinical trials for further predicted results, as well as the increasing desire for personalized therapy, are driving up demand for mice models. For example, in March 2023, National Institutes of Health researchers investigated an improved genetic animal model of Down syndrome. The unique mouse model provided prospective treatment possibilities for the illness.

The cancer segment is likely to hold the major share of the market in 2022

By application, the market is classified into cancer, immunological disease, infectious disease, and others. The cancer segment dominated the market in 2022 in terms of revenue and is expected to dominate the market during the forecast period. The market is expected to rise due to factors such as the translational importance of animal models in cancer research, the growing trend of precision oncology, and developments in tumor modeling methodologies. These models are used to assess the safety and effectiveness of anti-cancer treatments in clinical trials and preclinical testing. Furthermore, animal models assist researchers in testing the therapeutic index, bioavailability, and pharmacokinetic features of anti-cancer medicines prior to moving on with human clinical trials. Charles River Laboratories and Creative Biolabs are two firms that provide models for cancer research and treatment development.

The pharma and biotech companies segment is likely to hold the major share of the market in 2022

Based on end-user, the Animal Model Market is segmented into pharmaceutical & biotechnology companies, academic research institute, and contract research organization. In 2022, the pharma and biotech companies segment dominated the market in terms of revenue and is expected to be the same during the upcoming years. Companies’ increased attempts to create innovative treatment regimens are expected to boost the segment’s growth. Additionally, pharmaceutical firms’ increased medication discovery and development operations are contributing to category expansion. Furthermore, a large number of research-driven pharmaceutical businesses and their numerous activities are expected to boost market expansion.

The North America region is accounted for the majority of market share in 2022

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America has the biggest market share in terms of Animal Model Market value followed by Asia Pacific. The presence of significant companies and many strategic efforts by them are attributed to the region’s growth. Furthermore, expanding biomedical research and clinical trial spending are driving regional market expansion. Furthermore, advances in genetic modification and the increasing use of animal-based models for drug profiling and characterization are projected to open up new opportunities for market expansion.

Have a question for our analyst

Competitive Landscape

The key players studied in the Animal Model Market are The Jackson Laboratory, Charles River Laboratories, Crown Bioscience Inc., Janvier Labs, Hera Biolabs, Taconic Biosciences, Genoway S.A., Inotiv, Inc., Ozgene Pty Ltd., and BioSpherix, Ltd. among others.

Animal Model Market: Recent Developments

  • In January 2023, Charles River Laboratories has announced the addition of two additional NCG mice strains to their triple-immunodeficient mouse model portfolio, which are best suited for investigations in cancer, immunology, and infectious diseases.
  • In November 2022, Charles River Laboratories stated that it has inked a deal with Hera BioLabs to breed, distribute, market, and sell the SRG rat for use by the global preclinical research community.
  • In September 2022, Genoway S.A. and Sigma-Aldrich Co LLC established a new framework for their 2018 CRISPR/Cas9 strategic collaboration. GenOway will continue to spearhead the commercialization of Sigma-Aldrich’s CRISPR patent property in rodent species.
  • In June 2021, Genoway S.A. has announced a non-exclusive licence arrangement with ERS Genomics Limited. The arrangement gives GenOway access to ERS Genomics’ CRISPR/Cas9 patent portfolio in the past and in the future.
  • In December 2020, Genoway S.A. has established a strategic collaboration with Cyagen to commercialise high-quality preclinical humanised immune checkpoint and immunodeficient BRGSF mice models to charity and for-profit organisations in Asia-Pacific beginning in 2020.

Animal Model Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Animal Model Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future global Animal Model Market potential from 2022 to 2032 in terms of revenue ($ Million) and Volume (Units).
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the global Animal Model Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global Animal Model Market industry.

Animal Model Market Segmentation

By Animal Type

  • Rat
  • Mice
  • Guinea pigs
  • Rabbits
  • Others

By Application

  • Cancer
  • Immunological Disease
  • Infectious Disease
  • Others

By End-User

  • Pharmaceutical & Biotechnology Companies
  • Academic Research Institute
  • Contract Research Organization

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • The U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Netherlands
    • Sweden
    • Switzerland
    • Denmark
    • Finland
    • Russia
    • Rest of Europe
  • The Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Singapore
    • Indonesia
    • Taiwan
    • Malaysia
    • Rest of Asia-Pacific
  • Rest of the World
    • Latin America
    • The Middle East
    • Africa

Key Players